References
- Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4): 220-241.
- Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer. Cancer Lett . 2007; 252(2): 225-234.
- Miller VA. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs. 2008; 24(1): 27-33.
- Soria JC, Mok TS, Cappuzzo F, Jänne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat Rev. 2012; 38(5): 416-430.
- Cox DA, Der JC. Ras history: Small GTPases. 2010; 1(1): 2-27.
- Adjei A. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst. 2001; 93(14): 1062-1074.
- Monticone M, Biollo E, Maffei M, Donadini A, Romeo F, Storlazzi CT, et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer. 2008; 7(1): 92-104.
- Wicki A, Herrmann R, Christofori G. Kras in metastatic colorectal cancer. Swiss Med Wkly. 2010; 140(1): 13112-13119.
- Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, et al. Utility of serum DNA and pyrose-quencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 2013; 206(6): 73-80.
- Chang ET, Shema SJ, Wakelee HA, Clarke CA, Gomez SL. Uncovering disparities in survival after non-small cell lung cancer among Asian/Pacific Islander ethnic populations in California. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2248-2255.
- Arrieta O, Cardona AF, Martín C, López L, Rodríguez L, Bramuglia G. Updated frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015; 10(5): 838-843.
- Smits AJJ, Kummer JA, Hinrichs JWJ, Herder GJM, Scheidel-Jacobse KC, Jiwa NM. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol. 2012; 35(3): 189-196.
- Ciećkiewicz S, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: A Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12): 2800-2812.
- Unal OU, Oztop I, Calibasi G, Baskin Y, Koca D, Demir N. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in Western Turkey. Asian Pacific J Cancer Prev. 2013; 14(6): 3705-3709.
- Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific Region. J Thorac Oncol. 2015; 10(3): 438-445.
- Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. 2014; 4: 244.
- Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5): 339-346.
- Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25): 5900-5909.